CliffBio
small molecule

SIMBRINZA

BRIMONIDINE TARTRATE; BRINZOLAMIDE

Loss of exclusivityOctober 2030latest FDA-listed patent expiry
CompanyAlcon →See this company's full patent-cliff portfolio

Drug detail

Brand nameSIMBRINZA
Active ingredientBRIMONIDINE TARTRATE; BRINZOLAMIDE
Strength0.2%;1%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalApril 2013
Marketing statusRX

Listed patents

PatentExpiresType
9044484October 2030product
9421265June 2030product

More from Alcon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SIMBRINZA patent cliff — loss of exclusivity October 2030 | CliffBio